RxDoctor Payments Data

Aurelio Garcia Medina, MD

Internal Medicine · Ponce, PRNPI 1013101021

Payments from drug & device makers

$1,547in general payments, 2019–2025

Across 53 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$547
  • Johnson & Johnson$304
  • E.r. Squibb & Sons, L.L.C.$151
  • Boston Scientific$133
  • Bayer$125
  • Pfizer Pharmaceuticals LLC$124
  • plus $163 from 3 others

What the payments were for

  • Food & beverage$1,547100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)37$547
Johnson & Johnson7$304
E.r. Squibb & Sons, L.L.C.3$151
Boston Scientific1$133
Bayer1$125
Pfizer Pharmaceuticals LLC1$124
Dexcom, Inc.1$114
PBG Puerto Rico LLC1$28
AstraZeneca1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,547 in reported general payments places this provider in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,074
Medicare patients
18
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$41,075
JanumetSitagliptin Phos/Metformin Hcl29$24,596
JanuviaSitagliptin Phosphate13$23,353
JentaduetoLinagliptin/Metformin Hcl18$20,872
XareltoRivaroxaban17$20,717
JardianceEmpagliflozin14$17,927
BrilintaTicagrelor23$16,367
SynjardyEmpagliflozin/Metformin Hcl13$13,483
SynthroidLevothyroxine Sodium83$9,821
Janumet XrSitagliptin Phos/Metformin Hcl11$8,562
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,845
LantusInsulin Glargine,hum.Rec.Anlog45$5,720
Atorvastatin Calcium323$4,654
HumalogInsulin Lispro14$3,388
Alogliptin-MetforminAlogliptin Benz/Metformin Hcl12$3,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$304$20,71717 claims
AstraZenecaBrilinta$22$16,36723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →